{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:01:22Z","timestamp":1791475282219,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Branch atheromatous disease (BAD) is a subtype of ischemic stroke caused by perforating arteries occlusion due to proximal atherosclerosis of the arteries. Early neurological deterioration and recurrent stereotyped transient ischemic attacks are typical clinical manifestations of BAD. The optimal treatment for BAD has not been determined. This article explores a possible mechanism of BAD and effective treatment measures to prevent early progression and attack of transient ischemic events. This article explains the current status of intravenous thrombolysis, tirofiban, and argatroban for BAD and subsequent prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/bc.bc_56_22","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T01:30:50Z","timestamp":1670808650000},"page":"169-171","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Branch atheromatous disease and treatment"],"prefix":"10.4103","volume":"8","author":[{"given":"Honglian","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jun","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240830","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1212\/WNL.39.9.1246","article-title":"Intracranial branch atheromatous disease: A neglected, understudied, and underused concept","volume":"39","author":"Caplan","year":"1989","journal-title":"Neurology"},{"key":"R2-1-20240830","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.012","article-title":"Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease","volume":"22","author":"Deguchi","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R3-1-20240830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/PL00007852","article-title":"Spectrum of medial medullary infarction: Clinical and magnetic resonance imaging findings","volume":"249","author":"Kumral","year":"2002","journal-title":"J Neurol"},{"key":"R4-1-20240830","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s10072-013-1322-z","article-title":"Leukoaraiosis and NIHSS score help to differentiate subtypes of intracranial branch atheromatous disease in Southern Han Chinese patients with stroke","volume":"34","author":"Men","year":"2013","journal-title":"Neurol Sci"},{"key":"R5-1-20240830","doi-asserted-by":"crossref","first-page":"e73030","DOI":"10.1371\/journal.pone.0073030","article-title":"Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease","volume":"8","author":"Men","year":"2013","journal-title":"PLoS One"},{"key":"R6-1-20240830","first-page":"11","article-title":"Capsular warning syndrome \u2013 A case series and discussion on management dilemmas","volume":"69","author":"Sundar","year":"2021","journal-title":"J Assoc Physicians India"},{"key":"R7-1-20240830","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jocn.2016.04.011","article-title":"Intravenous tissue plasminogen activator in acute branch atheromatous disease: Does it prevent early neurological deterioration?","volume":"33","author":"Park","year":"2016","journal-title":"J Clin Neurosci"},{"key":"R8-1-20240830","doi-asserted-by":"crossref","first-page":"e100045","DOI":"10.1371\/journal.pone.0100045","article-title":"Inflammatory biomarkers in atherosclerosis: Pentraxin 3 can become a novel marker of plaque vulnerability","volume":"9","author":"Shindo","year":"2014","journal-title":"PLoS One"},{"key":"R9-1-20240830","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/ene.14249","article-title":"Elevated serum pentraxin 3 levels might predict the diagnosis of branch atheromatous disease at a very early stage","volume":"27","author":"Ninomiya","year":"2020","journal-title":"Eur J Neurol"},{"key":"R10-1-20240830","doi-asserted-by":"crossref","first-page":"143","DOI":"10.14336\/AD.2020.0421","article-title":"Radiomics in stroke neuroimaging: Techniques, applications, and challenges","volume":"12","author":"Chen","year":"2021","journal-title":"Aging Dis"},{"key":"R11-1-20240830","first-page":"196","article-title":"A combined hematoxylin-eosin, alkaline phosphatase and high-resolution microradiographic study of lacunes","volume":"9","author":"Challa","year":"1990","journal-title":"Clin Neuropathol"},{"key":"R12-1-20240830","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3389\/fneur.2020.00581","article-title":"Efficacy and safety of intravenous thrombolysis on acute branch atheromatous disease: A retrospective case-control study","volume":"11","author":"Wu","year":"2020","journal-title":"Front Neurol"},{"key":"R13-1-20240830","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12883-019-1522-0","article-title":"Capsular warning syndrome: Clinical analysis and treatment","volume":"19","author":"He","year":"2019","journal-title":"BMC Neurol"},{"key":"R14-1-20240830","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/STROKEAHA.119.026240","article-title":"Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis","volume":"50","author":"Wu","year":"2019","journal-title":"Stroke"},{"key":"R15-1-20240830","first-page":"1","article-title":"Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease","volume":"48","author":"Liu","year":"2020","journal-title":"J Int Med Res"},{"key":"R16-1-20240830","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/STROKEAHA.110.599662","article-title":"Safety of tirofiban in acute ischemic stroke: The SaTIS trial","volume":"42","author":"Siebler","year":"2011","journal-title":"Stroke"},{"key":"R17-1-20240830","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/FJC.0000000000001077","article-title":"Assessing the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy in progressive ischemic stroke patients","volume":"78","author":"Zhang","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"R18-1-20240830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/svn-2018-000163","article-title":"Intravenous tirofiban therapy for patients with capsular warning syndrome","volume":"4","author":"Li","year":"2019","journal-title":"Stroke Vasc Neurol"},{"key":"R19-1-20240830","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.2022.12584","article-title":"Effect of intravenous tirofiban versus placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: The RESCUE BT randomized clinical trial","volume":"328","author":"Qiu","year":"2022","journal-title":"JAMA"},{"key":"R20-1-20240830","first-page":"557","article-title":"Safety of dual antiplatelet therapy with argatroban in patients with acute ischemic stroke","volume":"70","author":"Nagakane","year":"2018","journal-title":"Brain Nerve"},{"key":"R21-1-20240830","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.038","article-title":"The importance of combined antithrombotic treatment for capsular warning syndrome","volume":"27","author":"Kamo","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R22-1-20240830","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/ehm.10.53","article-title":"Pharmacology of argatroban","volume":"3","author":"Jeske","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"R23-1-20240830","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1161\/STROKEAHA.121.036356","article-title":"Dual antiplatelet therapy plus argatroban prevents early neurological deterioration in branch atherosclerosis disease","volume":"53","author":"Xu","year":"2022","journal-title":"Stroke"},{"key":"R24-1-20240830","doi-asserted-by":"crossref","first-page":"415","DOI":"10.14336\/AD.2020.0709","article-title":"NIHSS Consciousness Score combined with ASPECTS is a favorable predictor of functional outcome post endovascular recanalization in stroke patients","volume":"12","author":"Cheng","year":"2021","journal-title":"Aging Dis"},{"key":"R25-1-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000442577","article-title":"Branch atheromatous disease: A clinically meaningful, yet unproven concept","volume":"41","author":"Petrone","year":"2016","journal-title":"Cerebrovasc Dis"},{"key":"R26-1-20240830","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.015","article-title":"Comparison of functional outcome between lacunar infarction and branch atheromatous disease in lenticulostriate artery territory","volume":"25","author":"Niimi","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R27-1-20240830","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/bc.bc_72_20","article-title":"Beyond reperfusion: Enhancing endogenous restorative functions after an ischemic stroke","volume":"6","author":"Wills","year":"2020","journal-title":"Brain Circ"},{"key":"R28-1-20240830","first-page":"139","article-title":"Functional recoveries of patients with branch atheromatous disease after rehabilitation: Comparison with other types of cerebral infarction and importance of stratification by clinical categories","volume":"39","author":"Okuda","year":"2021","journal-title":"Restor Neurol Neurosci"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_56_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:17:43Z","timestamp":1787757463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_56_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_56_22","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}